Welcome to our dedicated page for TuHURA Biosciences news (Ticker: HURA), a resource for investors and traders seeking the latest updates and insights on TuHURA Biosciences stock.
TuHURA Biosciences develops immuno-oncology therapeutics designed to address resistance to cancer immunotherapies. Company news centers on its clinical-stage pipeline, including IFx-2.0, an innate immune agonist being studied as adjunctive therapy with Keytruda in advanced or metastatic Merkel Cell Carcinoma, and TBS-2025, a VISTA-inhibiting monoclonal antibody for mutNPM1 relapsed or refractory acute myeloid leukemia.
Recurring updates also cover the Delta Opioid Receptor technology used in immune-modulating antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells. Other company developments include financial results, clinical operations leadership, investor-conference communications, financing arrangements and Nasdaq listing compliance matters.
TuHURA Biosciences (NASDAQ:HURA) reported second quarter 2026 results and a corporate update for the period ended June 30, 2026. The company highlighted progress across its immuno-oncology pipeline, including filing an IND for VISTA-inhibiting antibody TBS-2025 in molecularly defined subsets of AML and other blood cancers, aligned with prior FDA guidance.
TuHURA detailed a $50 million term credit facility and royalty transaction from its largest shareholder, bearing 12% annual interest and maturing on April 21, 2031, which it expects will extend its cash runway into 2028. The company outlined multiple anticipated milestones through 2027 for IFx-2.0, TBS-2025 and its MDSC inhibitor ADCs, including potential orphan drug designations and initiation of a Phase 1b/2 AML trial.
As of June 30, 2026, TuHURA reported $1.0 million in cash and cash equivalents and approximately 63.7 million common shares outstanding. Second quarter 2026 R&D expenses were $6.6 million versus $4.9 million a year earlier, while G&A expenses were $2.1 million versus $1.9 million. Net cash used in operating activities was $13.0 million for the first half of 2026, partly offset by $10.6 million in net cash from financing activities, including ATM and credit facility proceeds.
TuHURA Biosciences (NASDAQ:HURA) announced that President and CEO James A. Bianco, M.D., will present at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA, on Wednesday, August 12, 2026 at 12:30 p.m. ET. A live registration link and an archived webcast will be available via the Investor Section of TuHURA's website, alongside an “Ask Me Anything” interview with Dr. Bianco.
TuHURA Biosciences (NASDAQ:HURA) filed an Investigational New Drug (IND) application with the FDA for TBS-2025, a VISTA inhibiting antibody, in molecularly defined subsets of AML and other blood cancers.
The IND follows FDA guidance, supports a combined Phase 1b/2 design, and targets trial initiation in the second half of 2026, including relapsed/refractory AML and high-risk MDS populations.
TuHURA Biosciences (NASDAQ:HURA) reported first quarter 2026 results and a corporate update. The company secured a $50 million credit facility and royalty transaction, extending its anticipated cash runway into 2028. TuHURA received FDA Orphan Drug Designation for IFx-2.0 in stage IIB–IV cutaneous melanoma and outlined key milestones across IFx-2.0, VISTA antibody TBS-2025, and MDSC-inhibiting ADCs. At March 31, 2026, cash and equivalents were $6.3 million, with R&D expenses of $5.2 million and G&A expenses of $2.3 million for the quarter.
TuHURA Biosciences (NASDAQ:HURA), a Phase 3 immuno-oncology company, announced that President and CEO James A. Bianco, M.D. will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference in New York City.
The session is scheduled for Tuesday, May 19, 2026 at 2:00 pm ET, with live and archived webcasts available on TuHURA's investor relations website.
TuHURA Biosciences (NASDAQ:HURA) entered a $50 million credit facility with an affiliate of its largest stockholder to fund clinical programs, including IFx-2.0 through anticipated Phase 3 top-line results and TBS-2025 milestones, extending cash runway into 2028.
The facility allows monthly draws, bears 12% annual interest with monthly interest payments, principal due April 21, 2031, is secured by company assets, and includes a low- to mid-single-digit royalty on future IFx-2.0 commercial sales.
TuHURA Biosciences (NASDAQ:HURA) appointed Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations effective April 7, 2026. Garofalo brings over 20 years of Phase I-IV drug and biologic development experience and will oversee day-to-day clinical operations while working with Craig Tendler, M.D.
Her background includes enabling an oversubscribed $305M Series F at Parabilis, managing a portfolio of 200+ oncology trials at EMD Serono, and directing three IND submissions in 12 months at Arcus Biosciences.
TuHURA Biosciences (NASDAQ:HURA) reported 2025 results and a corporate update, highlighting a Phase 3 SPA-backed IFx-2.0 trial in first-line Merkel Cell Carcinoma, a completed $10.5 million acquisition of Kineta rights to TBS-2025, and planned clinical and preclinical milestones through 2027.
Financials show $3.6 million cash at 12/31/2025, R&D of $20.5M, G&A of $7.6M, net operating outflows of $27.7M, and $21.2M gross raised in 2025 financings.
TuHURA Biosciences (NASDAQ: HURA) announced that Dr. Craig L. Tendler will provide strategic and operational services consistent with a Chief Medical Officer while remaining on the Board, to lead development of the VISTA‑blocking antibody TBS‑2025 in AML and other blood cancers.
Dr. Tendler brings ~30 years of oncology and hematology development experience, multiple regulatory approvals and prior leadership on JNJ's menin inhibitor program; TuHURA reports preliminary FDA feedback on early development plans.
TuHURA Biosciences (NASDAQ:HURA) announced it regained compliance with Nasdaq's $1.00 minimum bid price requirement after the company's common stock closed at $1.00 or greater for 11 consecutive business days from Feb 10, 2026 through Feb 25, 2026, and Nasdaq closed the matter on Feb 26, 2026.
The company said it is progressing enrollment in its Phase 3 accelerated approval trial for IFX-2.0 in front-line Merkel Cell Carcinoma, readying TBS 2025 for a Phase 2 study in relapsed/refractory NPM1 mutated AML, and advancing preclinical proof-of-concept for immune modulating antibody drug conjugates.